Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
IOVA

IOVA - Iovance Biotherapeutics Inc Stock Price, Fair Value and News

$2.75-0.23 (-7.72%)
Market Closed

63/100

IOVA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

63/100

IOVA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$3.18

Target 3M

$2.77

Target 6M

$2.9

IOVA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IOVA Price Action

Last 7 days

9.6%

Last 30 days

-1.4%

Last 90 days

41.0%

Trailing 12 Months

-55.6%

IOVA RSI Chart

IOVA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IOVA Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-2.67

Price/Sales (Trailing)

4.23

EV/EBITDA

-2.29

Price/Free Cashflow

-3.01

IOVA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$3.18

Target 3M

$2.77

Target 6M

$2.9

IOVA Fundamentals

IOVA Revenue

Revenue (TTM)

250.4M

Rev. Growth (Yr)

15.2%

Rev. Growth (Qtr)

12.52%

IOVA Earnings

Earnings (TTM)

-397.6M

Earnings Growth (Yr)

-9.23%

Earnings Growth (Qtr)

18.27%

IOVA Profitability

Operating Margin

17.71%

EBT Margin

-159.06%

Return on Equity

-56.62%

Return on Assets

-43.94%

Free Cashflow Yield

-33.19%

IOVA Investor Care

Shares Dilution (1Y)

26.54%

Diluted EPS (TTM)

-1.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025212.7M241.5M250.4M0
202441.9M82.6M123.3M164.1M
20230001.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Iovance Biotherapeutics Inc

IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
 CEO
 WEBSITEiovance.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES503

Iovance Biotherapeutics Inc Frequently Asked Questions

IOVA is the stock ticker symbol of Iovance Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Iovance Biotherapeutics Inc is 1.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check IOVA's fair value in chart for subscribers.

The fair value guage provides a quick view whether IOVA is over valued or under valued. Whether Iovance Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Iovance Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IOVA.

As of Wed Jan 28 2026, IOVA's PE ratio (Price to Earnings) is -2.67 and Price to Sales (PS) ratio is 4.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IOVA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Iovance Biotherapeutics Inc has provided -0.075 (multiply by 100 for percentage) rate of return.